"Giusti’s aggressive approach to myeloma research has been controversial among some academic scientists, who argue that it’s unrealistic—even counterproductive—for patients and their advocates to think that with enough money and the right business model they can buy a cure. "
In this week's New Yorker, an article about a pharmaceutical company who pays for the speed at which drugs are developed. Is it advantageous to pay money as an incentive to meet deadlines, or does this only hurt the quality of the work that scientists are doing? Especially in a business such as this, communication is key to getting things done, and getting things done right.
http://www.newyorker.com/reporting/2008/01/28/080128fa_fact_groopman
